Focus

1、$Tencent (00700.HK) $The interim dividend will be paid by way of in-kind distribution of class A common shares of JD.com Group

Tencent announced on the Hong Kong Stock Exchange that the board of directors announced that on December 23, 2021, the resolution will be issued on the basis of one Class A common share of JD.com Group for every 21 shares held by eligible shareholders, to the shareholders whose names are on the register of shareholders of the Company on the record date according to their respective shareholdings in the Company at that time. A special interim dividend of 457326671 Class An ordinary shares of JD.com Group indirectly held by the Company through Huang River (assuming that there is no change in the total number of shares issued from the date of this announcement to the record date) is declared by way of physical distribution, and the number of shares of the JD.com Group will be reduced to the nearest whole number. Non-eligible shareholders will not be entitled to receive JD.com Group shares, but will receive cash in lieu of JD.com Group shares in respect of their shares on the basis of one Class An ordinary share of JD.com Group for every 21 shares held on the record date.

2、$JD.com Group-SW (09618.HK) $Tencent's shareholding in the company will be reduced from 17% to 2.3%.

JD.com Group announced on the Hong Kong Stock Exchange that the company learned that Tencent Co., Ltd. currently indirectly holds about 17.0% of the issued shares of the company, and announced that it will allocate to its shareholders about 460 million Class A common shares of JD.com Group. After the allocation, Tencent's shareholding in the company is about 2.3%, and the shareholders of Tencent, who obtained the shares of the company in this distribution, will become shareholders of the company.

3、$China Evergrande Group (03333.HK) $The risk mitigation committee is mobilizing a wide range of resources to try to defuse group risks

China Evergrande Group HKEx announced that in view of the risks currently faced by the Group, the risk Resolution Committee of China Evergrande Group Group is mobilizing a wide range of resources, and will actively maintain communication with creditors, strive to resolve group risks and safeguard the legitimate rights and interests of all parties.

4、Poly Xiexin Energy (03800.HK) $Completed HK $5 billion financing, Hillhouse Capital and others participated in this round of placing

Poly Xiexin Energy announced on the Hong Kong Stock Exchange that the company's current round of 2.037 billion shares was completed, with a net income of about HK $4.994 billion. According to the company's plan, in addition to a small part of the funds used for general operating purposes, more than 90% of the funds raised will be used for granular silicon projects in Inner Mongolia and Jiangsu. Participating in the placing of Poly Xiexin shares are all long-term investors, mainly led by Hillhouse Capital and Xinhua assets.

5、$Wuxi Biologics (02269.HK) $Repurchase of 2.2825 million shares at a cost of HK $200 million on December 22nd

Wuxi Biologics announced that it spent HK $200 million to buy back 2.2825 million shares at a price of HK $86.1-HK $88.30 per share.

6、$Green Leaf Pharmaceutical (02186.HK) $Grant Jinsai Pharmaceutical the exclusive commercialization right of Lis' Mingtou skin patch to Chinese mainland

Green Leaf Pharmaceutical announced that Greenleaf Switzerland, a wholly-owned subsidiary of the Group, had entered into an agreement with Kinsey Pharmaceutical, under which Kinsey Pharmaceutical acquired the exclusive commercial rights of Mingtou patch (single-day patch) and Lis' Mingtou patch (multi-day patch) in Chinese mainland. Jinsai Pharmaceutical will make a down payment of RMB 70 million to Greenleaf Switzerland after the relevant agreement is signed. The total transaction value of the agreement is up to 216 million yuan.

7、$Kai Ming Medical-B (02500.HK) $Venus-PowerX, the first international fully released recyclable dry valve product, successfully completed the world's first clinical application.

Qiming Medical-B announced that the company independently developed a new generation of transcatheter aortic valve replacement (TAVR) system and the world's first fully released recyclable dry valve product Venus-PowerX, which successfully completed the first clinical trial for human (First-in-Man,FIM) in West China Hospital of Sichuan University on December 21st, with Professor Chen Mao, Director of Cardiology of the hospital as the principal researcher (PI).

Operation data

China Reinsurance (01508): the original premium income of Dadi property Insurance from January to November was 39.625 billion yuan.

Resume trading and suspend trading

Baihong Industries (02299): achieve all the guidelines for resumption of trading from December 23rd

Baobaoshu Group (01761): Startree and potential sellers are still finalizing the possibility of resuming trading on December 23rd

Increase and decrease holdings

COSCO Shipping Holdings (01919): cumulative increase of 62.487 million H shares by controlling shareholders

Haohai Biotechnology (06826): Lou Guoliang plans to reduce his stake in the company by no more than 0.4502%

Xuhui Yongsheng Services (01995) was awarded a total of 100000 shares by Zhou Hongbin, Executive Director and President.

Merger and acquisition and sale

China Metallurgical (01618) subsidiary intends to sell accounts receivable with a book value not exceeding 4.2 billion yuan.

China Communications Construction (01800) acquires 21% stake in Zhongjiao Lease

Shandong Gold Mining (01787) intends to sell the assets of Building 3, Shuntai Plaza, 2000 Shunhua Road, Jinan High-tech Zone for 415 million yuan.

Additional placement

Poly Xiexin Energy (03800) completed the placement of 2.037 billion shares and raised a net HK $4.994 billion.

Investment and operation

China Evergrande Group (03333): the risk Mitigation Committee is mobilizing a wide range of resources to resolve group risks.

Jiahe Bio-B (06998) applied to the BELLBERRY Clinical Research Ethics Committee for GB263T's first human clinical trial.

Zhangjiang, Fudan (01349): the trial application of Helmpofen for the treatment of port wine stains is accepted by the FDA of the United States.

Zhejiang Shanghai, Hangzhou and Ningbo (00576): Zhejiang Merchants Futures plan to introduce investors through public listing

Xiansheng Pharmaceutical Co., Ltd. (02096): troxil for injection is included in CDE priority review varieties.

Lutheran Glass (00868) signs 2021 Glass supply Agreement

Green Leaf Pharmaceuticals (02186) awarded Jinsai Pharmaceutical the exclusive commercial right of Lis' transparent skin patch to Chinese mainland.

Hot coin technology (01611): memorandum of understanding with Astana International Financial Centre on potential cooperation on matters relating to innovation and digital assets

Qiming Medical-B (02500): Venus-PowerX, the first international fully released recyclable dry valve product, successfully completed the world's first clinical application.

Repurchase cancellation

Wuxi Biologics (02269) spent HK 200 million to buy back 2.2825 million shares on December 22nd

Lutheran Glass (00868) spent HK $58.394 million to buy back 3.119 million shares on December 22nd

HSBC Holdings PLC (00005) spent 14.438 million pounds to buy back 3.255 million shares on December 21.

Shimao Service (00873) spent HK $5.3921 million to buy back 1 million shares on December 22nd

Tianlun Gas (01600) spent HK $9.499 million to buy back 1.17 million shares on December 22nd

Net Dragon (00777) spent HK $3.871 million to buy back 200000 shares on December 22nd

Longguang Group (03380) spent HK $2.855 million to buy back 500000 shares on December 22nd.

Fosun (00656) spent HK $4.0531 million to buy back 500000 shares on December 22nd

Jinxin Reproduction (01951) spent HK $4.5995 million to buy back 515500 shares on December 22nd

China Feihe Limited (06186) spent HK $5.3115 million to buy back 500000 shares on December 22nd

CK Hutchison (00001) spent HK $4.93 million to buy back 100000 shares on December 22nd

Equity incentive

China Communications Service (00552) plans to grant about 207 million stock appreciation rights to 981 incentive targets.